| A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth A Roesch, M Fukunaga-Kalabis, EC Schmidt, SE Zabierowski, ... Cell 141 (4), 583-594, 2010 | 1307 | 2010 |
| Melanoma D Schadendorf, ACJ Van Akkooi, C Berking, KG Griewank, R Gutzmer, ... The Lancet 392 (10151), 971-984, 2018 | 1267 | 2018 |
| Cancer stem cell definitions and terminology: the devil is in the details P Valent, D Bonnet, R De Maria, T Lapidot, M Copland, JV Melo, ... Nature Reviews Cancer 12 (11), 767-775, 2012 | 808 | 2012 |
| Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells A Roesch, A Vultur, I Bogeski, H Wang, KM Zimmermann, D Speicher, ... Cancer cell 23 (6), 811-825, 2013 | 679 | 2013 |
| Melanoma D Schadendorf, DE Fisher, C Garbe, JE Gershenwald, JJ Grob, A Halpern, ... Nature reviews Disease primers 1 (1), 1-20, 2015 | 647 | 2015 |
| Immunotherapy in melanoma: recent advances and future directions C Franklin, E Livingstone, A Roesch, B Schilling, D Schadendorf European Journal of Surgical Oncology (EJSO) 43 (3), 604-611, 2017 | 300 | 2017 |
| Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging I Stoffels, S Morscher, I Helfrich, U Hillen, J Leyh, NC Burton, ... Science translational medicine 7 (317), 317ra199-317ra199, 2015 | 298 | 2015 |
| Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised … L Zimmer, E Livingstone, JC Hassel, M Fluck, T Eigentler, C Loquai, ... The Lancet 395 (10236), 1558-1568, 2020 | 227 | 2020 |
| Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases H Niessner, A Forschner, B Klumpp, JB Honegger, M Witte, A Bornemann, ... Cancer medicine 2 (1), 76-85, 2013 | 144 | 2013 |
| Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma A Roesch Oncogene 34 (23), 2951-2957, 2015 | 137 | 2015 |
| Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population M Fukunaga-Kalabis, G Martinez, TK Nguyen, D Kim, A Santiago-Walker, ... Oncogene 29 (46), 6115-6124, 2010 | 136 | 2010 |
| A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma C Krepler, K Sproesser, P Brafford, M Beqiri, B Garman, M Xiao, ... Cell reports 21 (7), 1953-1967, 2017 | 134 | 2017 |
| Transcriptional profiling of human endogenous retrovirus group HERV-K (HML-2) loci in melanoma K Schmitt, J Reichrath, A Roesch, E Meese, J Mayer Genome biology and evolution 5 (2), 307-328, 2013 | 125 | 2013 |
| Inverse regulation of melanoma growth and migration by O rai1/STIM 2‐dependent calcium entry H Stanisz, S Saul, CSL Müller, R Kappl, BA Niemeyer, T Vogt, M Hoth, ... Pigment cell & melanoma research 27 (3), 442-453, 2014 | 114 | 2014 |
| Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma MV Heppt, A Roesch, B Weide, R Gutzmer, F Meier, C Loquai, KC Kähler, ... European Journal of Cancer 81, 36-44, 2017 | 103 | 2017 |
| Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient S Herz, T Höfer, M Papapanagiotou, JC Leyh, S Meyenburg, ... European journal of cancer 67, 66-72, 2016 | 102 | 2016 |
| Loss of EphB6 expression in metastatic melanoma C Hafner, F Bataille, S Meyer, B Becker, A Roesch, M Landthaler, T Vogt International journal of oncology 23 (6), 1553-1559, 2003 | 99 | 2003 |
| Aetiology, comorbidities and cofactors of chronic leg ulcers: retrospective evaluation of 1 000 patients from 10 specialised dermatological wound care centers in Germany F Jockenhöfer, H Gollnick, K Herberger, G Isbary, R Renner, M Stücker, ... International wound journal 13 (5), 821-828, 2016 | 96 | 2016 |
| RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas M Kunz, H Löffler-Wirth, M Dannemann, E Willscher, G Doose, J Kelso, ... Oncogene 37 (47), 6136-6151, 2018 | 92 | 2018 |
| Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas A Roesch, B Becker, S Meyer, P Wild, C Hafner, M Landthaler, T Vogt Modern Pathology 18 (9), 1249-1257, 2005 | 90 | 2005 |
